Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Seaweed and mediterranean diet show promise for Pre-Diabetes immune health

NCT ID NCT06147323

Disease control Sponsor: University of Roehampton Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a seaweed supplement or a Mediterranean-style diet could help people with pre-diabetes control their blood sugar and strengthen their immune system against infections. Researchers studied 45 adults with pre-diabetes, measuring changes in blood glucose, insulin, gut health, and inflammation. The goal was to find simple dietary changes that could reduce the risk of developing type 2 diabetes and related health problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Adults aged between 18 and 60 years, with * Fasting blood glucose level of 5.6-6.9mmol/L or impaired HbA1c (HbA1c level of 5.7%-6.4%) * Fasting blood glucose level below 5.6mmol/L or HbA1c level below 5.7%. * For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English. Exclusion criteria * People with a current diagnosis or clinical history of T2DM * People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, uncontrolled hypertension, cancer or major psychiatric or cognitive problems. * People who are already participating in a weight loss programme * People receiving drug treatment for pre-diabetes (eg, metformin) * People with a history of long-term use of medicines known to influence glucose metabolism (eg, corticosteroids) * People with elevated liver enzymes (alanine aminotransferase ≥300 IU/L, aspartate aminotransferase ≥300 IU/L) * People who take antibiotics or bacterial agents (Probiotics) within 1 month * Pregnant women, women ready for pregnancy, and nursing mothers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre diabetes

Contacts and locations

Locations

  • Health Sciences Research Centre, Life Sciences Department, University of Roehampton

    London, UK, SW15 4JD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.